{"schema_version":"secwatch.filing_event.v1","accession":"0000355811-26-000021","form_type":"8-K","ticker":"GNTX","cik":"0000355811","company_name":"GENTEX CORP","filed_at":"2026-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.578735+00:00","generated_at":"2026-05-15T04:19:18.236340+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Gentex Q1: core sales up 2% despite production drop; China revenue falls 29% on tariffs; guides FY rev higher","bullets":["Q1 consolidated net sales $675.4M (+17% YoY); core Gentex (ex-VOXX) $586.8M (+2% vs -3% global production).","GAAP EPS $0.46 (vs $0.42), adjusted EPS $0.48 (vs $0.43); net income $98.5M up from $94.9M.","FY2026 revenue guidance raised to $2.65-2.75B (from $2.60-2.70B); gross margin unchanged 34-35%.","China revenue down 29% YoY to ~$28M; cumulative IEEPA tariffs paid directly ~$42M, $15M capitalized in inventory.","Repurchased 3.3M shares for $71.6M in Q1; 32.6M shares remaining under buyback plan."],"urls":{"canonical":"https://secwatch.observer/filing/0000355811-26-000021","json":"https://secwatch.observer/filing/0000355811-26-000021.json","markdown":"https://secwatch.observer/filing/0000355811-26-000021.md","text":"https://secwatch.observer/filing/0000355811-26-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/355811/000035581126000021/0000355811-26-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/355811/000035581126000021/gntx-20260424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T04:19:18.236340+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"053327a82ca61e1f2937559466ed937aa4df0030","claim":"GENTEX CORP reported first quarter ended March 31, 2026 results: revenue $675.4 million, net income $98.5 million, EPS $0.46.","evidence_excerpt":"medical devices, and consumer electronics, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Highlights • Net sales: Consolidated $675.4 million; core Gentex (ex‐VOXX) $586.8 million • Gross margin: Consolidated 33.8%; core Gentex (ex‐VOXX) 34.0% • Consolidated Income from operations: (GAAP) $123.7 million; core Gentex","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/355811/000035581126000021/0000355811-26-000021-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"$675.4 million"},{"label":"Net income","value":"$98.5 million"},{"label":"EPS","value":"$0.46"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}